GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » ROE %

Phreesia (Phreesia) ROE %

: -47.51% (As of Jan. 2024)
View and export this data going back to 2019. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Phreesia's annualized net income for the quarter that ended in Jan. 2024 was $-122.6 Mil. Phreesia's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was $258.0 Mil. Therefore, Phreesia's annualized ROE % for the quarter that ended in Jan. 2024 was -47.51%.

The historical rank and industry rank for Phreesia's ROE % or its related term are showing as below:

PHR' s ROE % Range Over the Past 10 Years
Min: -52.07   Med: -42.34   Max: -14.95
Current: -52.07

During the past 7 years, Phreesia's highest ROE % was -14.95%. The lowest was -52.07%. And the median was -42.34%.

PHR's ROE % is ranked worse than
86.49% of 607 companies
in the Healthcare Providers & Services industry
Industry Median: 4.07 vs PHR: -52.07

Phreesia ROE % Historical Data

The historical data trend for Phreesia's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia Annual Data
Trend Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
ROE %
Premium Member Only Premium Member Only - -14.95 -34.72 -49.96 -50.77

Phreesia Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.01 -54.45 -57.60 -49.95 -47.51

Competitive Comparison

For the Health Information Services subindustry, Phreesia's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phreesia ROE % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's ROE % distribution charts can be found below:

* The bar in red indicates where Phreesia's ROE % falls into.



Phreesia ROE % Calculation

Phreesia's annualized ROE % for the fiscal year that ended in Jan. 2024 is calculated as

ROE %=Net Income (A: Jan. 2024 )/( (Total Stockholders Equity (A: Jan. 2023 )+Total Stockholders Equity (A: Jan. 2024 ))/ count )
=-136.885/( (287.819+251.449)/ 2 )
=-136.885/269.634
=-50.77 %

Phreesia's annualized ROE % for the quarter that ended in Jan. 2024 is calculated as

ROE %=Net Income (Q: Jan. 2024 )/( (Total Stockholders Equity (Q: Oct. 2023 )+Total Stockholders Equity (Q: Jan. 2024 ))/ count )
=-122.584/( (264.598+251.449)/ 2 )
=-122.584/258.0235
=-47.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. ROE % is displayed in the 30-year financial page.


Phreesia  (NYSE:PHR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-122.584/258.0235
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-122.584 / 380.02)*(380.02 / 372.4865)*(372.4865 / 258.0235)
=Net Margin %*Asset Turnover*Equity Multiplier
=-32.26 %*1.0202*1.4436
=ROA %*Equity Multiplier
=-32.91 %*1.4436
=-47.51 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2024 )
=Net Income/Total Stockholders Equity
=-122.584/258.0235
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-122.584 / -121.716) * (-121.716 / -118.312) * (-118.312 / 380.02) * (380.02 / 372.4865) * (372.4865 / 258.0235)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0071 * 1.0288 * -31.13 % * 1.0202 * 1.4436
=-47.51 %

Note: The net income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Phreesia ROE % Related Terms

Thank you for viewing the detailed overview of Phreesia's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phreesia (Phreesia) Business Description

Traded in Other Exchanges
Address
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Executives
Balaji Gandhi officer: Chief Financial Officer PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman officer: General Counsel & Secretary 315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn officer: SVP, Human Resources C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig director, officer: Chief Executive Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff officer: See Remarks C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky officer: SVP, Life Sciences C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts officer: Chief Operating Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg officer: Principal Accounting Officer BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson director C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen officer: Chief Financial Officer PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar director 305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub director C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill 10 percent owner C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453